Scientists Discover Hidden Immune Brake SLAMF6 That Lets Cancer Escape Treatment
A newly identified molecule called SLAMF6 exhausts cancer-fighting T cells from within — and blocking it may revive failed immunotherapies.
Summary
Scientists at the University of Montreal have identified SLAMF6, a molecule on immune cells that acts as a hidden brake on the body's ability to fight cancer. Unlike most known immune suppressors that require tumor interaction, SLAMF6 activates on T cells independently, weakening their attack, reducing durable immune memory, and accelerating exhaustion. The team developed monoclonal antibodies that block SLAMF6, restoring T cell strength and producing strong anti-tumor responses in mice. Published in Nature, this discovery is especially promising for cancer patients who no longer respond to existing immunotherapies like PD1 and PDL1 inhibitors. Early clinical trials in humans are the next planned step.
Detailed Summary
Cancer immunotherapy has transformed oncology, but a frustrating reality remains: many patients either never respond or eventually stop benefiting from treatments like PD1 and PDL1 inhibitors. A new discovery published in Nature may help explain why — and point toward a solution.
Researchers led by Dr. André Veillette at the Université de Montréal identified SLAMF6, a molecule sitting on the surface of T cells that functions as an internal immune brake. What makes it unusual is how it operates: most known immune checkpoints require a signal from tumor cells to suppress the immune response. SLAMF6 is self-activating — it triggers suppression directly on T cells without needing external input from the cancer itself.
When SLAMF6 engages, it reduces T cells' tumor-killing capacity, limits the production of long-lasting memory immune cells, and accelerates immune exhaustion — a state where T cells effectively burn out and lose their effectiveness. This mechanism may be a key reason why some tumors stay ahead of the immune system even during active treatment.
To counter this, the team developed monoclonal antibodies designed to prevent SLAMF6 from binding to itself and triggering its suppressive signals. In laboratory and mouse studies, these antibodies increased T cell activation, boosted durable immune cell populations, reduced exhaustion, and produced measurable anti-tumor responses. The researchers report the antibodies outperform all existing SLAMF6-targeting approaches.
The clinical implications are significant. These antibodies could form the basis of a new immunotherapy class, potentially used alone or alongside existing treatments. They may be particularly valuable for patients with solid tumors or blood cancers who have exhausted current options. However, results are so far limited to mouse models and human cell cultures. Early-stage human clinical trials are the critical next step before any conclusions about human efficacy and safety can be drawn.
Key Findings
- SLAMF6 is a self-activating immune brake on T cells that suppresses cancer-fighting ability without tumor interaction
- Blocking SLAMF6 with monoclonal antibodies restored T cell strength and produced anti-tumor responses in mice
- New antibodies reduced T cell exhaustion and increased durable immune memory cell populations
- This approach may benefit patients who no longer respond to PD1 or PDL1 checkpoint inhibitor therapies
- Early-stage human clinical trials for solid tumors and blood cancers are the planned next step
Methodology
This is a research summary based on a study published in Nature, a top-tier peer-reviewed journal, lending strong source credibility. The research was conducted at the Montreal Clinical Research Institute using mouse tumor models and human T cell laboratory experiments. As a news report summarizing primary research, specific statistical details and full methodology require review of the original publication.
Study Limitations
Results are currently limited to mouse models and human cell culture experiments — human clinical efficacy and safety remain unproven. The article is a press-release-style summary and may omit key methodological details, effect sizes, or limitations noted in the full Nature paper. Clinical availability is likely years away pending successful trial completion.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.